8^th European Immunology Conference June 29-July 01, 2017 Madrid, Spain

Thomas Böldicke, PhD, Helmholtz Centre for Infection Research, Department Structural and Functional Protein Research, Inhoffenstr. 7, 38124 Braunschweig, Germany

Immunology, Intracellular antibodies.

Thomas Grundström completed his doctorate at Umeå University in 1981 and his Medical degree in 1982. Dr. Grundström was post-doc 1982-1984 in the laboratory of prof. Pierre Chambon, Strasbourg, France, where he characterised the first discovered enhancer of transcription. He is professor at the department of Molecular Biology at Umeå University since 1994. Dr. Grundström discovered the first direct Ca2+/calmodulin inhibition of a transcription factor (Corneliusen et al., Nature, 1994) and has characterized the Ca2+ regulation of many regulatory proteins with a focus on the immune system. Dr. Grundström is presently studying regulation of production of high affinity antibodies

Immunology, Molecular Biology

Professor Lu’s research has focused on studying immune dysregulations in autoimmune diseases. During last ten years, his laboratory has been exploring novel strategies for the treatment of rheumatoid arthritis. His team was among the first to successfully treat autoimmune arthritis by targeting the cytokine B-cell activating factor in a preclinical study, which has significant therapeutic implications for the effective treatment of rheumatoid arthritis. Professor Lu is an internationally recognized expert in the field of autoimmunity. He is the Councilor of Federation of Immunological Societies of Asia-Oceania and has served as Chairman of Hong Kong Society for Immunology. He has published over 120 peer-reviewed papers in leading immunology and rheumatology journals.

Identification of genes involved in regulating lymphocyte development and function. Regulation of lymphocyte apoptosis in the quality control and homeostatic regulation. Gene silencing of novel TNF family cytokines for treating autoimmune disease.

Dr. Steve Zhou has served as the Director of Virology and Toxicology at Microbac Laboratories, Inc. since 2006. He has more than 16 years of experience virology, molecular biology and toxicology studies. He has to-date designed and directed over 500 viral inactivation studies for disinfectants and biopharmaceutical products. He is also a qualified clinical principle investigator. Dr. Zhou is an active publisher and a member of several scientific and trade associations and committees. He sits on the editorial board of the ARC Journal of Hematology. He has delivered many presentations in conferences. In 2015, he was invited to a scientific expert panel by the U.S. Environmental Protection Agency (EPA).

Immunology

Roswitha Gropp has over 25 years of experience in preclinical development and inflammatory diseases. She recently took on a different view considering the inflammatory process in UC as an uncontrolled wound healing process. This hypothesis assumes that epithelial damage induces the release of signals to evoke a Th2 characterized inflammatory response that ultimately results in repair of the colon. Using agent based modeling first disease maps were developed to describe the inflammatory milieu and the dynamics of the inflammatory response. This approach together with immunological profiling of patients allows for a better understanding of underlying mechanisms ultimately leading to individualized therapies.

Immunology